Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Relay Therapeutics Inc (RLAY)

Relay Therapeutics Inc (RLAY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,258,394
  • Shares Outstanding, K 132,742
  • Annual Sales, $ 25,550 K
  • Annual Income, $ -341,970 K
  • 60-Month Beta 1.66
  • Price/Sales 45.73
  • Price/Cash Flow N/A
  • Price/Book 1.54
Trade RLAY with:

Options Overview Details

View History
  • Implied Volatility 71.88% ( -3.76%)
  • Historical Volatility 69.83%
  • IV Percentile 22%
  • IV Rank 16.00%
  • IV High 269.51% on 10/20/23
  • IV Low 34.23% on 05/30/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 122
  • Volume Avg (30-Day) 38
  • Put/Call OI Ratio 0.27
  • Today's Open Interest 932
  • Open Int (30-Day) 942

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.72
  • Number of Estimates 8
  • High Estimate -0.64
  • Low Estimate -0.75
  • Prior Year -0.81
  • Growth Rate Est. (year over year) +11.11%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.95 +59.19%
on 07/02/24
9.77 -2.97%
on 07/23/24
+2.54 (+36.60%)
since 06/21/24
3-Month
5.70 +66.32%
on 04/24/24
9.77 -2.97%
on 07/23/24
+3.58 (+60.68%)
since 04/23/24
52-Week
5.70 +66.32%
on 04/24/24
12.63 -24.94%
on 07/31/23
-2.91 (-23.49%)
since 07/21/23

Most Recent Stories

More News
5 Biotech Stocks With 26% Upside Potential or More

As biotech stocks swing back into favor on Wall Street, here's a look at five picks that could deliver significant gains, according to analysts.

$SPX : 5,555.74 (-0.16%)
NVO : 133.28 (+0.08%)
BIIB : 224.29 (-1.03%)
KNSA : 26.29 (+22.91%)
SWTX : 37.77 (+2.55%)
RLAY : 9.48 (+7.73%)
ADPT : 4.20 (+0.96%)
GS : 492.15 (+1.05%)
Unlocking AI investment opportunities in healthcare

AI is revolutionizing healthcare by improving diagnosis and accelerating drug discovery. An often-overlooked sector with a wealth of AI opportunities.

INTC : 32.95 (-1.26%)
NVDA : 122.59 (-0.77%)
RXRX : 8.58 (+5.41%)
RLAY : 9.48 (+7.73%)
EXAI : 5.37 (+3.67%)
RENB : 1.3300 (+3.10%)
BTAI : 1.1900 (-0.83%)
The Global Metastatic Breast Cancer Treatment Market Expected To Reach $31 Billion By 2028

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:PFE),(NASDAQ:OCEA),(NYSE:NVS),(NASDAQ:RLAY) EQNX::TICKER_END

ONCY : 1.0200 (unch)
ONC.TO : 1.42 (unch)
PFE : 29.50 (-0.34%)
OCEA : 1.1400 (-1.72%)
NVS : 107.70 (-0.95%)
RLAY : 9.48 (+7.73%)
The Global Metastatic Breast Cancer Treatment Market Expected To Reach $31 Billion By 2028

/PRNewswire/ -- Metastatic breast cancer is the advanced stage of breast cancer, including cases wherein cancer has spread to the other parts of the body from...

ONC.TO : 1.42 (unch)
ONCY : 1.0200 (unch)
PFE : 29.50 (-0.34%)
OCEA : 1.1400 (-1.72%)
NVS : 107.70 (-0.95%)
RLAY : 9.48 (+7.73%)
Evolution of Oncology Treatments Giving New Hope to Those Diagnosed with Breast Cancer

FN Media Group Presents USA News Group News Commentary   Vancouver, BC – March 24, 2023 – USA News Group  –  Treatments for various forms of breast cancer continue to evolve, with several new...

BCTX : 0.7041 (+2.04%)
ONCY : 1.0200 (unch)
ONC.TO : 1.42 (unch)
CTMX : 1.4400 (-0.69%)
BCT.TO : 0.97 (+4.30%)
RLAY : 9.48 (+7.73%)
HOLX : 78.10 (-0.36%)
Evolution of Oncology Treatments Giving New Hope to Those Diagnosed with Breast Cancer

/PRNewswire/ -- USA News Group - Treatments for various forms of breast cancer continue to evolve, with several new breakthroughs being labeled as landmark in...

BCTXW : 0.1599 (+5.41%)
ONC.TO : 1.42 (unch)
BCT.TO : 0.97 (+4.30%)
ONCY : 1.0200 (unch)
CTMX : 1.4400 (-0.69%)
BCTX : 0.7041 (+2.04%)
RLAY : 9.48 (+7.73%)
HOLX : 78.10 (-0.36%)
Breast Cancer Treatment Options Evolved Over the Last 12 Months, Bringing More Hope for 2023

USA News Group – Treatments for various forms of breast cancer continue to evolve, with several new breakthroughs being labeled as landmark in nature and giving hope to families dealing with a fateful...

BCTX : 0.7041 (+2.04%)
ONCY : 1.0200 (unch)
ONC.TO : 1.42 (unch)
CTMX : 1.4400 (-0.69%)
BCT.TO : 0.97 (+4.30%)
RLAY : 9.48 (+7.73%)
HOLX : 78.10 (-0.36%)
Foundation Medicine and Relay Therapeutics Collaborate to Develop FoundationOne®CDx as a Companion Diagnostic for Relay’s Investigational FGFR2 Inhibitor, RLY-4008

Today Foundation Medicine, Inc. , a pioneer in molecular profiling for cancer, and Relay Therapeutics (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process...

RLAY : 9.48 (+7.73%)
Relay Therapeutics to Announce Second Quarter 2022 Financial Results and Corporate Highlights

CAMBRIDGE, Mass., July 28, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the...

RLAY : 9.48 (+7.73%)
Relay Therapeutics Discloses Anticipated Registrational Path for RLY-4008 in Cholangiocarcinoma and Growing Breast Cancer Franchise at Virtual Analyst and Investor Event

End-of-phase 1 meeting with the U.S. Food and Drug Administration (FDA) resulted in alignment on the design of a single arm trial for pan-FGFR (FGFRi)...

RLAY : 9.48 (+7.73%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Average short term outlook on maintaining the current direction.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Relay Therapeutics Inc. is a clinical-stage precision medicines company. It focuses on enhancing small molecule therapeutic discovery in targeted oncology. The company's product pipeline consist RLY-1971, RLY-4008 and RLY-PI3K1047 which are in clinical stage. Relay Therapeutics Inc. is based in Cambridge,...

See More

Key Turning Points

3rd Resistance Point 11.03
2nd Resistance Point 10.40
1st Resistance Point 9.94
Last Price 9.48
1st Support Level 8.85
2nd Support Level 8.22
3rd Support Level 7.76

See More

52-Week High 12.63
Fibonacci 61.8% 9.98
Last Price 9.48
Fibonacci 50% 9.16
Fibonacci 38.2% 8.35
52-Week Low 5.70

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar